tbuckley/cabot-search huggingface dataset:
Abstract B34: PDGFR-ID4-Notch axis is a common signaling pathway activated in glioma stem cells and endothelial cells
Authors: Hye-Min Jeon, Hyunggee Kim
Journal: Cancer Research (2015)

Abstract Glioma stem cells (GSCs), which reside within the perivascular niche (PVN) to maintain self-renewal capacity, are responsible for glioblastoma initiation, progression, and recurrence. However, the molecular mechanisms controlling GSCs and endothelial cells in the PVN are poorly understood. Here, we report that PDGF-driven activation of nitric oxide (NO) synthase increases NO-dependent ID4 expression, which promotes Jagged-Notch activity through miR-129 suppression in GSCs and endothelial cells. ID4 also increases PDGF-PDGFR signaling in a direct or miR-129-dependent manner, which drives the PDGFR-NO-ID4 signaling in GSCs and endothelial cells. This signaling circuit promotes tumor progression along with increased GSC self-renewal and growth of tumor vasculature in the PVN, which is dramatically suppressed by Notch inhibitor. ID4 levels correlate positively with NOS2, Hes1, and Hey1 and negatively with miR-129 in primary GSCs. Thus, targeting the PDGFR-NO-ID4 signaling circuit and Notch activity in the PVN might serve as an efficacious therapeutic modality for glioblastoma. Citation Format: Hye-Min Jeon, Hyunggee Kim. PDGFR-ID4-Notch axis is a common signaling pathway activated in glioma stem cells and endothelial cells. [abstract]. In: Proceedings of the AACR Special Conference: Advances in Brain Cancer Research; May 27-30, 2015; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2015;75(23 Suppl):Abstract nr B34.
Nationwide outbreak of Salmonella enterica serotype Give infections in infants in France, linked to infant milk formula, September 2008
Authors: N Jourdan, S Le Hello, G Delmas, J Clouzeau, C Manteau, B Désaubliaux, V Chagnon, F Thierry-Bled, N Demare, F  X Weill, H de Valk
Journal: Eurosurveillance (2008)

On Thursday 18 September 2008, the hospital of Nantes in west France informed the District Health Office of a case of salmonellosis in an exclusively bottle-fed infant. On Monday morning 22 September, two additional cases of salmonellosis in infants were reported by the hospital of Niort in southwest France. The serotype of the three cases was unknown at that time.
A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment
Authors: E. Calura, L. Paracchini, R. Fruscio, A. DiFeo, A. Ravaggi, J. Peronne, P. Martini, G. Sales, L. Beltrame, E. Bignotti, G. Tognon, R. Milani, L. Clivio, T. Dell'Anna, G. Cattoretti, D. Katsaros, E. Sartori, C. Mangioni, L. Ardighieri, M. D'Incalci, S. Marchini, C. Romualdi
Journal: Annals of Oncology (2016)
Abstract P5-07-15: Breast cancer estrogen receptor scoring in tissue microarrays: Specialist breast pathologist versus automation
Authors: LB Jordan, S Akbar, CA Purdie, AM Thompson, SJ McKenna
Journal: Cancer Research (2016)

Abstract Rationale: Tissue microarrays (TMAs) have become a valuable resource for biomarker expression in translational research. Immunohistochemical (IHC) assessment of TMAs is the principal method for analyzing protein expression in large numbers of patient samples efficient with conservation of tissue. However, manual IHC assessment of TMAs remains a challenging and laborious task. With advances in image analysis, computer generated analyses of TMAs have the potential to lessen the burden of expert pathologist review. Computerized ER scoring relies on tumor localization. Aim: The objective of this study was to compare the effectiveness of a locally developed automated invasive tumor location system with the skills of specialist breast pathologists. Methods: In this study, tumor localization for estrogen receptor (ER) scoring was evaluated comparing computer- generated segmentation masks with those of two specialist breast pathologists. Automated tumor localization was achieved using a novel image analysis algorithm, which labeled compact groups of pixels called superpixels. Machine learning techniques were adopted to model color, shape and textural properties of superpixels in a rotation invariant manner, suitable for histopathology images. The resulting automatically and manually-obtained segmentation masks were used to obtain IHC scores for thirty-two ER stained invasive breast cancer TMA samples using FDA-approved IHC scoring software. Results: Pixel-level comparisons showed lower agreement between automated and manual segmentation masks (κ = 0.84) than between pathologists' masks (κ = 0.91). However, this had little impact on computed IHC scores (Allred method; κ = 0.91, Quickscore method; κ = 0.92). Conclusion: The automated system provides sufficiently consistent measurements for standardized IHC analysis of nuclear staining in TMAs from large clinical trials. Citation Format: Jordan LB, Akbar S, Purdie CA, Thompson AM, McKenna SJ. Breast cancer estrogen receptor scoring in tissue microarrays: Specialist breast pathologist versus automation. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-07-15.
Late cardiac status in long-term survivors of childhood high-risk ALL 8 years after continuous or bolus infusion of doxorubicin: The DFCI Childhood ALL 91-01 randomized trial.
Authors: S. E. Lipshultz, S. R. Lipsitz, T. L. Miller, D. S. Neuberg, S. E. Dahlberg, S. D. Colan, L. B. Silverman, L. L. Cushman, J. M. Henkel, S. E. Sallan
Journal: Journal of Clinical Oncology (2010)

9513 Background: Continuous infusion (CI) of doxorubicin (DOX) reportedly reduces cardiotoxicity during or shortly after treatment in adults; however, its long-term cardioprotective effects in children are unclear. We determined the long-term cardiac outcome of children who received DOX by CI or bolus infusion (BI). Methods: Children with high-risk acute lymphoblastic leukemia were randomized on DFCI Protocol 91-01 (1991-5) to receive DOX 30 mg/m2/dose every 3 weeks (cumulative dose, 360 mg/m2) by either CI (over 48 hrs, n=52), or BI (within 1 hr, n=49). Serial echocardiograms were collected before, during, and after treatment. Patients had at minimum, 1 late echocardiogram at least 3 years post-treatment randomization. Echocardiograms were centrally remeasured. Left ventricular (LV) Z scores were derived from a healthy population. Results: Both treatment arms were similar in demographics and median follow-up (CI: 8.2; BI: 8.1 yrs postrandomization; p=0.81). At baseline, both arms showed normal measurements of LV structure and function. In contrast, late echocardiographic follow-up showed significant abnormalities of LV structure and function (depressed systolic function, systolic dilation, reduced wall thickness and mass) when compared to baseline measurements in both arms (Table, p*). There were no significant differences in cardiac parameters between the arms (Table, p†). There was no difference in event-free survival between arms (10-yr EFS: CI=83±4%; BI=78.2±4%; p=0.24). Conclusions: In late follow-up, patients in both treatment arms showed progressive cardiac dysfunction as measured by echocardiographic parameters. CI of DOX, compared to BI, did not diminish cardiotoxicity. Other cardioprotective strategies should be examined in this population. Differences between pre- and post-treatment echocardiographic Z scores Bolus infusion n = 49 Continuous infusion n = 52 LV measurement Median Z score p* Median Z score p* p† Fractional shortening −2.9 0.00 −2.3 0.00 0.95 Diastolic dimension 0.2 0.47 −0.4 0.77 0.28 Systolic dimension 1.3 0.00 0.7 0.00 0.56 Post. wall thickness −1.4 0.00 −1.3 0.00 0.98 Mass −1.5 0.00 −1.2 0.00 0.45 No significant financial relationships to disclose.
Abstract 13743: Critical Role of Endogenous Vascular Hydrogen Peroxide in Post-Ischemic Neovascularization: Studies Using Tie2-driven Endothelial Specific Catalase Transgenic Mice
Authors: Norifumi Urao, Seok-Jo Kim, Sudhahar Varadarajan, Gin-Fu Chen, Ronald D McKinney, Georg Kojda, Tohru Fukai, Masuko Ushio-Fukai
Journal: Circulation (2011)
Abstract B01: Biological consequences of histone mutations in the mammalian brain
Authors: Jon D. Larson, Lawryn H. Kasper, Helen R. Russell, Chunxu Qu, Xiaoyan Zhu, Peter J. McKinnon, Suzanne J. Baker
Journal: Cancer Research (2016)

Abstract Pediatric high-grade gliomas (HGGs) are devastating diseases with poor prognosis. The two-year survival for pediatric HGG ranges from 30%, for tumors arising in the cerebral cortex, to less than 10% for diffuse intrinsic pontine gliomas (DIPGs), which arise in the brainstem. Recurrent somatic mutations in histone H3 found in pediatric HGGs are rare in adult HGGs and may represent genetic drivers of disease. Mutually exclusive somatic heterozygous H3F3A or HIST1H3B mutations encoding a K27M variant of histone H3.3 or H3.1, respectively, are found in nearly 80 percent of DIPGs and 22 percent of non-brainstem HGG, where they occur predominantly in thalamic and other midline tumors. Strikingly, heterozygous H3F3A mutations encoding histone H3.3 G34R or G34V occur in approximately 14 percent of non-brainstem HGG, and are associated predominantly with cortical tumors arising in older children through young adulthood, suggesting a distinct developmental origin compared to the majority of tumors harboring K27M mutations. DNA methylation signatures and gene expression patterns distinguish G34R/V and K27M tumors, but the oncogenic mechanisms and brain region selectivity of these mutations are still uncertain. To study these mutations in the developing mammalian brain, we generated conditionally activated, epitope tagged H3f3a knock-in mice to express K27M, G34R or non-mutated H3.3 proteins. When activated in neural and glial precursor cells, extensive H3f3a expression was observed throughout the embryonic brain, and H3.3-K27M induced loss of H3K27me3, consistent with observations in K27M mutant DIPG tumor samples. Moreover, neural stem cells expressing H3.3-K27M demonstrated an in vitro growth advantage compared to H3.3-G34R or H3.3-WT expressing neural stem cells. We will present an analysis of the epigenetic landscape and gene expression signatures associated with the histone H3 K27M and G34R mutations in different brain regions as well as phenotypic analysis of the mutant mice. Citation Format: Jon D. Larson, Lawryn H. Kasper, Helen R. Russell, Chunxu Qu, Xiaoyan Zhu, Peter J. McKinnon, Suzanne J. Baker. Biological consequences of histone mutations in the mammalian brain. [abstract]. In: Proceedings of the AACR Special Conference on Chromatin and Epigenetics in Cancer; Sep 24-27, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2016;76(2 Suppl):Abstract nr B01.
Is bigger better?
Authors: J M Jessup
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.1.5 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7799042 Is bigger better? J M JessupxJ M JessupSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.1.5 First Page PDF © 1995 by American Society of Clinical Oncology
Clinical trials in the<i>BJD</i>:<i>how</i>to publish,<i>what</i>to publish and<i>where</i>to publish
Authors: M. Samimi, J. Albrecht, J. Batchelor, R.N. Matin
Journal: British Journal of Dermatology (2016)

The new structure of the BJD includes a section dedicated to the assessment of clinical trials.The goal is to publish studies with the highest methodological quality and clinical relevance, performed in accordance with relevant ethical standards.Clinical trial authors are now aware of three mandatory aspects to submitting randomized controlled trials (RCTs) to the BJD.Firstly, the need for prospective registration of the RCT in a suitable trial registry; secondly, the reporting of all outcomes, avoiding 'salami slicing'; and thirdly, the completion of the CONSORT checklist at submission, to ensure clear, transparent reporting.Although the CONSORT guidelines were developed more than two decades ago, 1 their application remains patchy.3][4][5] Although this research provides enlightening data on the quality of reporting in published studies, there were until now limited data regarding the topics covered in such trials.Having briefly reminded authors how to publish, this editorial will now focus on what to publishin other words, what the content of the clinical trials published in the BJD should include.This issue of the BJD includes a descriptive study of RCTs published in the top seven dermatological journals, including the BJD, between 2009 and 2013. 6Only 325 out of 11 478 published articles (2Á8%) were identified as RCTs.The BJD had the highest rate of RCTs, comprising 6Á1% of the BJD's articles, and accounting for 49Á2% of all RCTs published in these top seven dermatological journals.More than a decade ago, RCTs were estimated to constitute 7Á5% and 3Á5% of RCTs published in medical and surgical journals, respectively. 7It is therefore surprising that the percentage of RCTs, the 'gold standard' for generating reliable evidence, is so low in dermatology.However, the present study took into account only dermatological journals.It is not uncommon for published RCTs regarding one given disease to be widely scattered across specialty and nonspecialty journals. 8or example, a reader would have to read 114 journals in order to identify only 50% of the RCTs published in neurology in 2009. 8There is no information about such 'scattering' of published RCTs in skin diseases.However, this 'scattering phenomenon' is particularly obvious for specialties overlapping with others.This is the case in dermatology, which relates closely to oncology, rheumatology, internal medicine, infectious diseases, vascular diseases, wound healing and others.Scattering of publications may account for the under-representation of some overlapping diseases in top
Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels
Journal: American Journal of Psychiatry (1976)

Plasma chlorpromazine (CPZ) levels of 50 psychotic inpatients were measured by gas liquid chromatography; the clinical progress of 29 of these patients with acute psychoses was also assessed. CPZ levels of 50-300 ng/ml were usually associated with clinical improvement; there was also a relationship between CPZ levels and increases in certain symptoms. The 50-300 ng/ml level was best attained by doses of 400-800 mg/day. Trihexyphenidyl decreased plasma CPZ by a mean of 44.7% in 12 of 15 patients. A single 400-800-mg dose of CPZ at bedtime produced steady states equal to or better than those achieved with multiple doses. Those patients who failed to attain CPZ levels of more than 70 ng/ml despite doses of 400-1000 mg/day were receiving lithium throughout the study and had discharge diagnoses of manic-depressive psychosis, manic type, and schizo-affective schizophrenia--a finding with implications for future research.
Abstract 10016: Impact of Cardiac Devices on the Quality of Life in Pediatric Patients and Parents
Authors: Richard J Czosek, William J Bonney, Douglas Mah, Amy Cassedy, Tanel E Ronn, Jason R Imundo, Anoop K Singh, Mitchell Cohen, Christina Miyake, Fawley Kara, Bradley S Marino
Journal: Circulation (2011)

Background: Cardiac devices are increasingly utilized in children. The impact of devices on quality of life (QoL) in this population is poorly understood. Objective: To compare QoL scores between p...
Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC.
Authors: Helena Alexandra Yu, Geoffrey R. Oxnard, Alexander I. Spira, Leora Horn, Jared Weiss, Yan Feng, Howard Jack West, Giuseppe Giaccone, Tracey L. Evans, Ronan Joseph Kelly, Tanya Fleege, Srinivasu Poondru, Fei Jie, Koji Aoyama, Margaret A. Foley, Debbie Whitcomb, Anne Therese Keating, Andrew P. Krivoshik
Journal: Journal of Clinical Oncology (2015)

8083 Background: ASP8273 is a mutant selective, third generation irreversible inhibitor of EGFR activating mutations and the EGFR T790M resistance mutation, with less effect on wild type EGFR. Methods: In a phase I dose escalation study, subjects diagnosed with EGFR mutation positive NSCLC who were previously treated with an EGFR TKI were enrolled at multiple centers in the United States into dose escalation and expansion cohorts. ASP8273 was administered once daily at doses of 25 mg to 400 mg. Endpoints included safety and tolerability, PK and preliminary anti-tumor activity. Response expansion cohorts enrolled subjects with known EGFR T790M mutation and required submission of tissue samples for central confirmatory testing. Results: As of 08 January 2015, 35 subjects were enrolled; 24 subjects in 6 dose escalation cohorts (25-400 mg) and 11 subjects in 2 expansion cohorts (100-200 mg). The majority were female (71.4%), median age 65 (38-85), all (100%) received prior erlotinib, and the median number of prior therapies was 2. The most common treatment emergent AEs included nausea (9; 25.7%) & diarrhea (6; 17.1%); most were CTCAE Grade 1, manageable and none required dose reductions. Of 5 evaluable subjects enrolled at 400mg, 2 DLTs were observed requiring dose reduction including one event of G3 hyponatremia and one event of G3 anorexia. No ILD-like events, QTc prolongation or hyperglycemia have been reported. PK appeared to be dose proportional with mean t½ ~12 hours. Objective responses were observed at dose levels of ≥ 100mg. Among 25 subjects evaluable for response at the cutoff date, 7 (28%) subjects achieved PR and 15 (56%) achieved stable disease. Among 12 known T790M+ subjects, 3 PRs (25%) have been reported to date. Conclusions: ASP8273 appears well tolerated in doses ranging from 25-300 mg and has demonstrated anti-tumor activity at 100-400 mg dose levels. The most common toxicities include diarrhea and nausea which were G1 and manageable. Based on current Bayesian modeling, the MTD is anticipated to be 400 mg and the recommended phase 2 dose to be 300 mg. As the data for the T790M+ population is immature at the time of this abstract, updated data will be presented at the ASCO meeting. Clinical trial information: NCT02113813.
The Changing Paradigm of Treating Pancreatic Neuroendocrine Tumors
Authors: Renuka Iyer, Kaunteya Reddy
Journal: Journal of the National Comprehensive Cancer Network (2011)

Recently completed trials involving vatalanib, thalidomide, temozolomide, and pemetrexed, and ongoing clinical trials with sorafenib, AMG 479, bevacizumab, and temozolomide in the treatment of advanced NETs (available at www.ClinicalTrials.gov), are expected to further our understanding and refine our practices.
Vital Signs: Improvements in Maternity Care Policies and Practices That Support Breastfeeding — United States, 2007–2013
Authors: Cria G. Perrine, Deborah A. Galuska, Jaime L. Dohack, Katherine R. Shealy, Paulette E. Murphy, Laurence M. Grummer-Strawn, Kelley S. Scanlon
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

Although 80% of U.S. mothers begin breastfeeding their infants, many do not continue breastfeeding as long as they would like to. Experiences during the birth hospitalization affect a mother's ability to establish and maintain breastfeeding. The Baby-Friendly Hospital Initiative is a global program launched by the World Health Organization and the United Nations Children's Fund, and has at its core the Ten Steps to Successful Breastfeeding (Ten Steps), which describe evidence-based hospital policies and practices that have been shown to improve breastfeeding outcomes.Since 2007, CDC has conducted the biennial Maternity Practices in Infant Nutrition and Care (mPINC) survey among all birth facilities in all states, the District of Columbia, and territories. CDC analyzed data from 2007 (baseline), 2009, 2011, and 2013 to describe trends in the prevalence of facilities using maternity care policies and practices that are consistent with the Ten Steps to Successful Breastfeeding.The percentage of hospitals that reported providing prenatal breastfeeding education (range = 91.1%-92.8%) and teaching mothers breastfeeding techniques (range = 87.8%-92.2%) was high at baseline and across all survey years. Implementation of the other eight steps was lower at baseline. From 2007 to 2013, six of these steps increased by 10-21 percentage points, although limiting non-breast milk feeding of breastfed infants and fostering post-discharge support only increased by 5-6 percentage points. Nationally, hospitals implementing more than half of the Ten Steps increased from 28.7% in 2007 to 53.9% in 2013.Maternity care policies and practices supportive of breastfeeding are improving nationally; however, more work is needed to ensure all women receive optimal breastfeeding support during the birth hospitalization.Because of the documented benefits of breastfeeding to both mothers and children, and because experiences in the first hours and days after birth help determine later breastfeeding outcomes, improved hospital policies and practices could increase rates of breastfeeding nationwide, contributing to improved child health.
The Occurrence of Tumors of the Forestomach in Mice after Parenteral Administration of Methylcholanthrene: A Histopathologic and Genetic Analysis<xref ref-type="fn" rid="fn1"><sup>2</sup></xref><xref ref-type="fn" rid="fn2"><sup>3</sup></xref><xref ref-type="fn" rid="fn3"><sup>4</sup></xref>
Authors: Malcolm A. Bagshaw, Leonell C. Strong
Journal: JNCI Journal of the National Cancer Institute (1950)

Journal Article The Occurrence of Tumors of the Forestomach in Mice after Parenteral Administration of Methylcholanthrene: A Histopathologic and Genetic Analysis Get access Malcolm A. Bagshaw, Malcolm A. Bagshaw Search for other works by this author on: Oxford Academic PubMed Google Scholar Leonell C. Strong Leonell C. Strong Department of Anatomy, Yale University School of Medicine, New Haven, Conn. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 1, August 1950, Pages 141–175, https://doi.org/10.1093/jnci/11.1.141 Published: 01 August 1950 Article history Published: 01 August 1950 Received: 12 August 1950
New diagnoses of HTLV infection in England and Wales: 2002-2004
Authors: S Dougan, Alan Smith, J C Tosswill, K Davison, M Zuckerman, G P Taylor
Journal: Eurosurveillance (2005)

Human T cell lymphotropic viruses (HTLV) are retroviruses transmitted through breastfeeding, sexual contact, blood transfusion and injecting drug use. HTLV is endemic in the Caribbean, and parts of Africa, Japan and South America, with isolated foci in other areas. Infection is life long. Fewer than 5% of those infected progress to one of the HTLV-related diseases, but these are debilitating and often fatal. In England and Wales, laboratory and clinical reports of new HTLV diagnoses are routinely collected, including infections identified by the blood service since the introduction of anti-HTLV testing in August 2002. Between 2002 and 2004, 273 individuals were diagnosed with HTLV: 102 (37%) were male and 169 female (sex was not reported for two). Median ages at diagnosis were 54 and 50 years respectively. Clinical reports were received for 78% (212/273) individuals. Where reported, 58% (116/199) of individuals were of black Caribbean ethnicity and 29% (57/199) white; 87% (128/147) were probably infected heterosexually or through mother-to-child transmission; 45% (66/146) were probably infected in the Caribbean and 40% (59/146) in the United Kingdom. An appreciable number of HTLV infections continue to be diagnosed within England and Wales, with increases in 2002-2003 because of anti-HTLV testing of blood donations. While most infections diagnosed are directly associated with the Caribbean, transmission of HTLV infection is occurring within England and Wales. Specialist care services for HTLV-infected individuals and their families have improved in recent years, but prevention remains limited.